Dietitian Shares The 1 Cooking Oil Rule They Follow For A Healthy Heart
But this, experts claim, does not actually cause the inflammation it's accused of creating.
Kerry Beeson, a qualified nutritional therapist at Prep Kitchen, previously told HuffPost UK: 'Seed oils are objectively quite healthy, in that they're typically low in saturated fats.'
Writing for UC Davis Health, cardiovascular dietitian Margie Junker, who focuses on how our diets affect heart health, shared that she loved flax and peanut oil.
'Liquid plant oils are rich in unsaturated fats, which reduce low-density lipoprotein (LDL) cholesterol and heart disease risk,' she said.
But, she added, she avoids one particular type of fat for cooking.
'I stay away from fats that are hard at room temperature, such as bacon grease, shortening and margarine,' she told the university.
According to the World Cancer Research Fund, most cooking fats are higher in saturated fats.
'Too much fat in your diet, especially saturated fats, can raise your cholesterol, which increases the risk of heart disease,' the NHS added.
Other solid cooking fats include ghee, lard, and butter.
'I also avoid tropical oils (coconut, palm, and palm kernel), animal fats (butter and lard), and partially hydrogenated fats,' Junker shared.
Coconut oil has some of the highest saturated fat levels of all common cooking oils (86% to butter's 52%).
So, while Junker said she 'occasionally' adds coconut oil or butter to a dish for flavour, she chooses not to cook with them.
The British Heart Foundation recommends rapeseed oil as their best pick alongside olive oil, while Junker likes avocado oil most.
But though some oils and fats are higher in saturated fats than others, fats of any kind should not make up more than 35% of our diet.
'Current UK government guidelines advise cutting down on all fats and replacing saturated fat with some unsaturated fat,' the NHS shared.
Combining lower-saturated fats with moderation is key to better heart health.
Are Seed Oils Really Bad For You? I Asked A Nutritional Therapist
The Only 3 Cooking Oils Mary Berry Says We Need
Sorry, Your Essential Oils Are Essentially Useless
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
39 minutes ago
- Medscape
Growth Charts for Twins Improve Perinatal Risk Prediction
TOPLINE: New customised growth charts for twins (GROW-T), adjusted for maternal characteristics, more accurately predicted a small-for-gestational age (SGA)-associated risk for adverse perinatal outcomes than charts for singletons (GROW-S). METHODOLOGY: Researchers developed customised growth charts for twin pregnancies and compared them with singleton charts to evaluate their ability to identify SGA twins who are at an increased risk for adverse perinatal outcomes. They evaluated 8457 twin pregnancies (16,914 foetuses) from 127 NHS hospitals in the UK from January 2015 to February 2025, representing approximately two thirds of all NHS units. A mixed-effects linear regression analysis was performed to determine pregnancy-specific optimal weights at 37 weeks. Researchers compared GROW-T with GROW-S by calculating rates of the SGA-associated risk for stillbirth and adverse neonatal outcomes, such as the need for resuscitation, an Apgar score < 7 at 5 minutes, admission to the NICU, or neonatal death, using generalised estimating equations. TAKEAWAY: At 37 weeks, the average optimal weight of a twin was 389 g less than that of an equivalent singleton foetus. By pregnancy, 24.6% vs 64.9% of twins were classified as those with SGA (< 10th centile) according to GROW-T vs GROW-S; when analysed by individual foetuses, 13.8% vs 44.4% of twins were classified as those with SGA according to GROW-T vs GROW-S. Twins designated as SGA on the basis of GROW-T (odds ratio [OR], 7.2; 95% CI, 4.8-10.8) had a higher risk for stillbirth than those designated as SGA on the basis of GROW-S (OR, 2.8; 95% CI, 1.9-4.1). Twins classified as those with SGA on the basis of GROW-T had an increased need for resuscitation (OR, 1.3; 95% CI, 1.1-1.7), a lower Apgar score (< 7) at 5 minutes (OR, 1.8; 95% CI, 1.2-2.6), higher NICU admissions (OR, 1.3; 95% CI, 1.0-1.6), and an increased risk for neonatal death (OR, 5.4; 95% CI, 1.3-23.5). IN PRACTICE: "Our results add to the increasing evidence for adoption of twin specific charts," the authors wrote. "While adoption of twin specific charts is timely, implementation ought to be accompanied by evaluation in practice to monitor safety in different health service environments," they added. SOURCE: This study was led by Jason Gardosi, MD, Perinatal Institute, Birmingham, England, and was published online on August 01, 2025, in the American Journal of Obstetrics & Gynecology. LIMITATIONS: Ultrasound estimates of foetal weight in twins can be systematically overestimated, potentially affecting the accuracy of growth assessments. Chorionicity was not reported in the study cohort; however, the difference between growth curves of monochorionic and dichorionic twins was considered too small to be clinically relevant. DISCLOSURES: No funding information was provided for the study. All authors reported being employees of the Perinatal Institute, Birmingham, England. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
2 hours ago
- Yahoo
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025
Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) on track with data expected in all three indications this year with first-in-class potential in NT2 and IH ORX142 Phase 1 clinical trial for the treatment of select neurological and neurodegenerative disorders underway with data in acutely sleep-deprived healthy volunteers expected this year ORX489 in IND-enabling studies for the treatment of neuropsychiatric disorders BOSTON and LONDON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported financial results and business highlights for the second quarter ended June 30, 2025. 'As clinical validation of the orexin agonist class continues to grow, we believe Centessa is well positioned with a novel potential best-in-class OX2R agonist pipeline aimed at redefining the standard of care. This includes not only restoring normal wakefulness to meet the real-world needs of individuals with sleep-wake disorders, but also potentially addressing comorbidities such as excessive daytime sleepiness, impaired attention, cognitive deficits and fatigue across a range of neurological, neurodegenerative and neuropsychiatric conditions where there is unmet need,' said Saurabh Saha MD PhD, Chief Executive Officer of Centessa. Dr. Saha continued, 'ORX750, our most advanced OX2R agonist drug candidate, is progressing in an adaptive Phase 2a study that incorporates real-time drug development strategies aimed at optimizing dosing and best positioning ORX750 for planned registrational studies. This innovative approach continues to build our confidence in ORX750's potential to be a best-in-class OX2R agonist for the treatment of NT1, NT2 and IH, and potentially the first OX2R agonist to treat NT2 and IH. Our top priority remains the successful execution of the Phase 2a study, and we look forward to sharing data for ORX750 in all three indications this year.' 'In parallel, we recently initiated clinical development of ORX142, our second OX2R agonist drug candidate, with data in acutely sleep-deprived healthy volunteers also expected this year. With two programs advancing toward key clinical milestones and a broad pipeline of potentially transformative orexin therapies, we believe Centessa is positioned to become a long-term leader in the orexin space,' concluded Dr. Saha. Recent Highlights Following clearance of the Investigational New Drug application (IND) from the U.S. Food and Drug Administration (FDA) in June 2025, the Company initiated a Phase 1 first-in-human clinical trial of ORX142, with data in acutely sleep-deprived healthy volunteers expected this year. In April 2025, additional data from the Phase 1 study of ORX750 were presented in a poster session at the American Academy of Neurology (AAN) Annual Meeting. Along with previously disclosed Phase 1 data, the poster highlighted time-course curves for both the Maintenance of Wakefulness Test (MWT) and the Karolinska Sleepiness Scale (KSS) from the 5.0 mg dose cohort. At this dose, sustained effects were observed across the full 8-hour post-dose observation period, with mean sleep latency exceeding 30 minutes on the MWT and improvements in KSS scores compared to placebo. An abstract highlighting the adaptive design of the Company's Phase 2a CRYSTAL-1 study for ORX750, including an open-label long-term extension (LTE), has been accepted as a poster presentation at the World Sleep 2025 Congress being held on September 5–10, 2025, in Singapore. The abstract, Development of a Novel, Oral Orexin Receptor 2 Agonist, ORX750 for Treatment of Patients with Narcolepsy (type 1 and 2) and Idiopathic Hypersomnia, is available on the conference website. A copy of the poster will be available on the Centessa website at at the time of the poster presentation. OX2R Agonist Pipeline and Anticipated Upcoming Milestones ORX750: The Phase 2a CRYSTAL-1 study is ongoing with data in NT1, NT2 and IH expected in 2025. ORX142: The Phase 1 first-in-human study of ORX142 is ongoing with data in acutely sleep-deprived healthy volunteers expected in 2025. ORX489: Currently in IND-enabling studies. Second Quarter 2025 Financial Results Cash, Cash Equivalents and Investments: Cash, cash equivalents and investments totaled $404.1 million as of June 30, 2025. The Company expects its cash, cash equivalents and investments as of June 30, 2025 will fund operations into mid-2027. Research & Development (R&D) Expenses: R&D expenses were $42.7 million for the second quarter ended June 30, 2025, compared to $32.8 million for the second quarter ended June 30, 2024. General & Administrative (G&A) Expenses: G&A expenses were $11.9 million for the second quarter ended June 30, 2025, compared to $11.2 million for the second quarter ended June 30, 2024. Net Loss: Net loss was $50.3 million for the second quarter ended June 30, 2025, compared to $43.8 million for the second quarter ended June 30, 2024. About Centessa's Orexin Receptor 2 (OX2R) Agonist Program Orexin is a neuropeptide that regulates the sleep-wake cycle, leading to arousal and promoting wakefulness. Targeting the orexin pathway with novel orexin receptor 2 (OX2R) agonists represents a potential promising approach to address excessive daytime sleepiness (EDS), impaired attention, cognitive deficits and fatigue associated with a broad range of neurological, neurodegenerative and neuropsychiatric disorders. Centessa is developing a pipeline of potential best-in-class OX2R agonists, including ORX750 for the treatment of sleep-wake disorders including narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), ORX142 for the treatment of select neurological and neurodegenerative disorders, and ORX489 for the treatment of neuropsychiatric disorders. ORX750 is being evaluated in the Phase 2a CRYSTAL-1 study. For more information, visit ORX750, ORX142 and ORX489 are investigational candidates and have not been approved by the FDA or any other regulatory authority. About Centessa Pharmaceuticals Centessa Pharmaceuticals, plc is a clinical-stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients. We are pioneering a new class of potential therapies within our orexin receptor 2 (OX2R) agonist program for the treatment of EDS, impaired attention, cognitive deficits and fatigue across neurological, neurodegenerative and neuropsychiatric disorders. For more information, visit which does not form part of this release. Forward Looking Statements This press release contains forward-looking statements. These statements may be identified by words such as 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'objective,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'potential,' 'continue,' 'ongoing,' 'aim,' 'seek,' and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements, including statements related to the Company's ability to discover and develop transformational medicines for patients; its expectations for executing on the Company's pipeline; its expectations on its anticipated cash runway; the timing of commencement of new studies or clinical trials or clinical and preclinical data related to ORX750, ORX142, ORX489 and other OX2R agonist molecules; its ability to identify, screen, recruit and maintain a sufficient number of or any subjects in its existing and anticipated studies or clinical trials of ORX750, ORX142, ORX489 and other OX2R agonist molecules; its expectations on executing its research and clinical development plans and the timing thereof; its expectations as to the potential results and impact of each of its clinical programs and trials; the Company's ability to differentiate ORX750, ORX142, ORX489 and other OX2R agonist molecules from other treatment options, including those being developed by competitors; the development, design and therapeutic potential of ORX750, ORX142, ORX489 and other OX2R agonist molecules, including the potential for ORX750 to be a best-in-class OX2R agonist for the treatment of NT1, NT2 and IH, and potentially the first OX2R agonist to treat NT2 and IH; and regulatory matters, including the timing and likelihood of success of obtaining regulatory clearance or authorizations to initiate or continue clinical trials. Any forward-looking statements in this press release are based on our current expectations, estimates, assumptions and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the safety and tolerability profile of our product candidates; our ability to identify, screen and recruit a sufficient number of or any subjects in our existing and anticipated new studies or clinical trials of ORX750, ORX142, ORX489 or within anticipated timelines; our expectations relating to the clinical trials of ORX750 and ORX142, including the predicted timing of enrollment, the predicted efficacious doses of ORX750 and ORX142 and our ability to successfully conduct our clinical development of ORX750 and ORX142, our ability to protect and maintain our intellectual property position; business (including commercial viability), regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about the Company; risks inherent in developing product candidates and technologies; future results from our ongoing and planned clinical trials; our ability to obtain adequate financing, including through our financing facility with Oxford Finance, to fund our planned clinical trials and other expenses; trends in the industry; the legal and regulatory framework for the industry, including the receipt and maintenance of clearances to conduct or continue clinical testing; our operating costs and use of cash, including cash runway, cost of development activities and conducting clinical trials, future expenditures risks; the risk that any one or more of our product candidates will not be successfully developed and/or commercialized; the risk that the historical results of preclinical studies or clinical studies will not be predictive of future results in ongoing or future studies; economic risks to the United States and United Kingdom banking systems; and geo-political risks such as the Russia-Ukraine war, the Middle East conflicts or trade wars and impact of the imposition of tariffs. These and other risks concerning our programs and operations are described in additional detail in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and our other reports, which are on file with the U.S. Securities and Exchange Commission (SEC). We explicitly disclaim any obligation to update any forward-looking statements except to the extent required by law. Contact: Kristen K. Sheppard, Esq. SVP of Investor Relations investors@ Centessa Pharmaceuticals plcConsolidated Statements of Operations and Comprehensive Loss(unaudited)(amounts in thousands except share and per share data) Three Months EndedJune 30, 2025 Three Months EndedJune 30, 2024 Six Months EndedJune 30, 2025 Six Months EndedJune 30, 2024 License and other revenue $ — $ — $ 15,000 $ — Operating expenses: Research and development 42,741 32,815 76,184 55,467 General and administrative 11,912 11,165 24,246 24,603 Loss from operations (54,653 ) (43,980 ) (85,430 ) (80,070 ) Interest and investment income 4,380 3,240 12,270 5,831 Interest expense (2,884 ) (2,525 ) (5,761 ) (5,054 ) Other non-operating income (expense), net 3,592 154 4,618 (1,383 ) Loss before income taxes (49,565 ) (43,111 ) (74,303 ) (80,676 ) Income tax expense 778 705 2,175 1,186 Net loss (50,343 ) (43,816 ) (76,478 ) (81,862 ) Other comprehensive (loss) income: Foreign currency translation adjustment (479 ) (61 ) 164 (86 ) Unrealized (loss) gain on available for sale marketable securities, net of reclassification adjustment and tax (5 ) 33 (2,786 ) 188 Other comprehensive (loss) income (484 ) (28 ) (2,622 ) 102 Total comprehensive loss $ (50,827 ) $ (43,844 ) $ (79,100 ) $ (81,760 ) Net loss per ordinary share - basic and diluted $ (0.38 ) $ (0.40 ) $ (0.57 ) $ (0.78 ) Weighted average ordinary shares outstanding - basic and diluted 133,677,405 109,489,184 133,354,373 104,688,452 Centessa Pharmaceuticals plcCondensed Consolidated Balance Sheets(unaudited)(amounts in thousands) June 30, 2025 December 31, 2024 Total assets: Cash and cash equivalents $ 44,242 $ 383,221 Investments in marketable securities 359,888 98,956 Other assets 87,997 94,621 Total assets $ 492,127 $ 576,798 Total liabilities Other liabilities $ 37,663 $ 66,313 Long term debt 109,545 108,940 Total liabilities 147,208 175,253 Total shareholders' equity 344,919 401,545 Total liabilities and shareholders' equity $ 492,127 $ 576,798 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Review launched over reports of delayed response to faulty knee replacement part
Health officials have launched a review amid reports that action was not taken swiftly enough following problems with a knee replacement part. BBC's File on 4 reported patients were left immobile and addicted to painkillers due to issues with the joint replacement. Some medics have said they first started noticing issues with a part of a knee replacement made by American medical device company Zimmer Biomet around eight years ago. A product recall was not issued until December 2022. A standard total knee replacement has four parts – a femoral component, tibial tray, patellar component and a polyethylene insert. Concerns were raised about the tibial part – also known as 'NexGen Stemmed Option Tibial Component' – as experts found the implant was linked to higher revision rates compared to other models. A recall was led by the Medicines and Healthcare products Regulatory Agency (MHRA) in December 2022 after analysis of National Joint Registry data. Leading knee surgeon Professor Leela Biant said action was not taken quickly enough after problems arose. She told File on 4 that concerns were raised by herself and colleagues around eight years ago – five years before the product recall. 'The issue is their initial reluctance to acknowledge a problem and to not really engage with a process to evaluate these patients until they got to a situation where they had to,' she told the programme. In June 2022, a study was published in the journal Bone & Joint Open which suggested 'there is a fundamental issue with this NexGen implant design'. Patients have told the BBC about the impact on their lives. Debbie Booker, a manager for a company running retirement homes on the south coast, had a knee replacement operation at a local NHS hospital in 2016. Mrs Booker, from Southampton, described how it initially felt like the operation was a success but a year later she was suddenly 'in agony'. As a result of the pain she said she had to take powerful pain killers. 'I was on fentanyl and morphine. I was actually addicted to morphine and it took me a long time to actually come off the morphine because I was addicted,' she said. Medics found the implant had slipped out of place and she needed revision surgery. Another patient, known only as Diana, described how within three years of her left knee replacement surgery she went from being an active retiree to being sofa-bound. 'Every time I stood up I was standing on a broken leg and it was agony,' she told the programme. It also impacted surgeons who used the implant during their operations. One described how they became a surgical 'outlier', with higher revision rates than expected, after using the implant. File on 4 reported the implant had been used on 10,000 patients. Local NHS teams are responsible for reviewing and, where clinically necessary, replacing affected implants. A spokesperson for NHS England said: 'The safety of patients is the absolute priority for the NHS. 'Where issues are identified with any medical device, local NHS teams work swiftly to assess patients and provide replacement treatment where clinically necessary, in accordance with recommendations from the MHRA and device manufacturers. 'NHS England is currently reviewing the case involving Zimmer Biomet NexGen knee implants.' Zimmer Biomet has been approached for comment. The company told File on 4 in a statement: 'Zimmer Biomet is committed to the highest standards of patient safety, quality, and transparency. 'When new data becomes available, we act appropriately, responsibly, and in accordance with applicable regulatory requirements.'
